Wolfram E. Samlowski

5.4k citations

154 papers · 3.7k indexed · h-index 34

Impact in

Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cutaneous Melanoma Detection and Management
Immunology top 5%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction

Papers in ⓘ

Oncology 71
- Cancer Immunotherapy and Biomarkers 21
- Cutaneous Melanoma Detection and Management 20
- CAR-T cell therapy research 14
Dermatology 13

Co-authors: John R. McGregor (17 shared papers)John B. Hibbs (5 shared papers)Sancy A. Leachman (9 shared papers)Raymond A. Daynes (11 shared papers)Chang‐Yeol Yim (6 shared papers)Steven O’Day (9 shared papers)Neil R. Bastian (4 shared papers)Evan M. Hersh (4 shared papers)
Journals: Journal of Clinical Oncology (31 papers)Cancer (10 papers)Investigational New Drugs (8 papers)Journal of Immunotherapy (7 papers)Cellular Immunology (7 papers)
Partner nations: United States South Korea United Kingdom

In The Last Decade

Wolfram E. Samlowski

151 papers receiving 3.6k citations

Peers

Countries citing papers authored by Wolfram E. Samlowski

Since Specialization

Citations

This map shows the geographic impact of Wolfram E. Samlowski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wolfram E. Samlowski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wolfram E. Samlowski more than expected).

Fields of papers citing papers by Wolfram E. Samlowski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wolfram E. Samlowski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wolfram E. Samlowski. The network helps show where Wolfram E. Samlowski may publish in the future.

Co-authors

The 25 scholars most cited alongside Wolfram E. Samlowski, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Wolfram E. Samlowski Line = papers co-authored together Wolfram E. Samlowski links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 154 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma Investigational New Drugs ·Evan M. Hersh, Steven O’Day, John D. Powderly, Khuda Dad Khan, Anna C. Pavlick, Lee D. Cranmer, Wolfram E. Samlowski, Geoffrey Nichol, Michael Yellin, Jeffrey S. Weber	2010	237
2	Metastatic Melanoma in Pregnancy: Risk of Transplacental Metastases in the Infant Journal of Clinical Oncology ·April Alexander, Wolfram E. Samlowski, Douglas Grossman, Carol S. Bruggers, Ronald M. Harris, John J. Zone, R. Dirk Noyes, Glen M. Bowen, Sancy A. Leachman	2003	169
3	Evaluation of a 7-Day Continuous Intravenous Infusion of Decitabine: Inhibition of Promoter-Specific and Global Genomic DNA Methylation Journal of Clinical Oncology ·Wolfram E. Samlowski, Sancy A. Leachman, Mark Wade, Pamela B. Cassidy, Patricia Porter‐Gill, Leslie T. Busby, Richard Wheeler, Kenneth M. Boucher, F.A. Fitzpatrick, David A. Jones, Adam R. Karpf	2005	114
4	A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma Investigational New Drugs ·Karl D. Lewis, Wolfram E. Samlowski, John F. Ward, Joseph Catlett, Lee D. Cranmer, John M. Kirkwood, David H. Lawson, Eric J. Whitman, René González	2009	113
5	Value of positive myocardial technetium-99m-pyrophosphate scintigraphy in the noninvasive diagnosis of cardiac amyloidosis American Heart Journal ·Theodore A. Wizenberg, Jaroslaw Muz, Young H. Sohn, Wolfram E. Samlowski, Arnold M. Weissler	1982	99
6	Use of N-acetyl cysteine to increase intracellular glutathione during the induction of antitumor responses by IL-2. The Journal of Immunology ·Chang Yeol Yim, John B. Hibbs, J R McGregor, Raymond E. Galinsky, Wolfram E. Samlowski	1994	93
7	A phase 2 clinical trial of nab‐paclitaxel in previously treated and chemotherapy‐naive patients with metastatic melanoma Cancer ·Evan M. Hersh, Steven O’Day, Antoni Ribas, Wolfram E. Samlowski, Michael S. Gordon, Deganit E. Shechter, Alicia Clawson, René González	2009	91
8	Macrophage nitric oxide synthesis delays progression of ultraviolet light-induced murine skin cancers. PubMed ·Chang‐Yeol Yim, Neil R. Bastian, Jeffrey C. Smith, John B. Hibbs, Wolfram E. Samlowski	1993	91
9	Effects of supravital fluorochromes used to analyze the in vivo homing of murine lymphocytes on cellular function Journal of Immunological Methods ·Wolfram E. Samlowski, Bekkie A. Robertson, Bradley K. Draper, Elizabeth Prystas, John R. McGregor	1991	79
10	Population-Based Analysis of Prognostic Factors and Survival in Familial Melanoma Journal of Clinical Oncology ·Scott R. Florell, Kenneth M. Boucher, Gilda Garibotti, John Astle, Richard A. Kerber, Geraldine P. Mineau, Charles L. Wiggins, R. Dirk Noyes, Alexander Tsodikov, Lisa Cannon‐Albright, John J. Zone, Wolfram E. Samlowski, Sancy A. Leachman	2005	75
11	Phase 1 study of escalating-dose OncoGel® (ReGel®/paclitaxel) depot injection, a controlled-release formulation of paclitaxel, for local management of superficial solid tumor lesions Anti-Cancer Drugs ·Svetislava J. Vukelja, Stephen P. Anthony, James C. Arseneau, Barry S. Berman, Casey Cunningham, John Nemunaitis, Wolfram E. Samlowski, Kirk Fowers	2007	74
12	Soluble Biodegradable Polymer-Based Cytokine Gene Delivery for Cancer Treatment Molecular Therapy ·Anurag Maheshwari, Ram I. Mahato, John R. McGregor, Sang‐oh Han, Wolfram E. Samlowski, Jong-Sang Park, Sung Wan Kim	2000	73
13	N-Acetylcysteine Protects Melanocytes against Oxidative Stress/Damage and Delays Onset of Ultraviolet-Induced Melanoma in Mice Clinical Cancer Research ·Murray A. Cotter, Joshua Thomas, Pamela B. Cassidy, Kyle Robinette, Noah Jenkins, Scott R. Florell, Sancy A. Leachman, Wolfram E. Samlowski, Douglas Grossman	2007	73
14	Phase II Study of Erlotinib in Patients With Locally Advanced or Metastatic Papillary Histology Renal Cell Cancer: SWOG S0317 Journal of Clinical Oncology ·Michael S. Gordon, Michael A. Hussey, Raymond B. Nagle, Primo N. Lara, Philip C. Mack, Janice Dutcher, Wolfram E. Samlowski, Joseph I. Clark, David I. Quinn, Chong‐Xian Pan, David Crawford	2009	72
15	Induction of iron-derived EPR signals in murine cancers by nitric oxide. Evidence for multiple intracellular targets. Journal of Biological Chemistry ·Neil R. Bastian, Chang‐Yeol Yim, John B. Hibbs, Wolfram E. Samlowski	1994	70
16	Clinical Cancer Advances 2011: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology Journal of Clinical Oncology ·Nicholas J. Vogelzang, Steven I. Benowitz, Sylvia Adams, Carol Aghajanian, Susan M. Chang, ZoAnn E. Dreyer, Pasi A. Jänne, Andrew H. Ko, Greg A. Masters, Olatoyosi Odenike, Jyoti D. Patel, Bruce J. Roth, Wolfram E. Samlowski, Andrew D. Seidman, William D. Tap, Jennifer S. Temel, Jamie H. Von Roenn, Mark G. Kris	2011	68
17	Modification of the murine immune system by glucocorticosteroids: Alterations of the tissue localization properties of circulating lymphocytes Cellular Immunology ·Hun‐Taeg Chung, Wolfram E. Samlowski, Raymond A. Daynes	1986	66
18	Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS) Cancer ·Wolfram E. Samlowski, Gordon A. Watson, Michael Wang, Ganesh Rao, Paul Klimo, Kenneth M. Boucher, Dennis C. Shrieve, Randy L. Jensen	2007	64
19	A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Leukemia Research ·Chatchada Karanes, Kenneth J. Kopecky, David R. Head, Michael R. Grever, Harry E. Hynes, Eric H. Kraut, Richard Vial, Alan Lichtin, Sucha Nand, Wolfram E. Samlowski, Frederick R. Appelbaum	1999	64
20	A Phase II Trial of Imatinib Mesylate in Merkel Cell Carcinoma (Neuroendocrine Carcinoma of the Skin) American Journal of Clinical Oncology ·Wolfram E. Samlowski, James Moon, Ralph J. Tuthill, Michael C. Heinrich, Naomi Balzer-Haas, Stuart A. Merl, Ronald C. DeConti, John A. Thompson, Merle Witter, Lawrence E. Flaherty, Vernon K. Sondak	2010	63

About Wolfram E. Samlowski

Wolfram E. Samlowski is a scholar working on Oncology, Dermatology, Cancer Research, Pulmonary and Respiratory Medicine and Otorhinolaryngology, having authored 154 papers that have together received 3.7k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (21 papers), Cutaneous Melanoma Detection and Management (20 papers), Cancer Genomics and Diagnostics (17 papers), Renal cell carcinoma treatment (16 papers), Melanoma and MAPK Pathways (15 papers), CAR-T cell therapy research (14 papers), Brain Metastases and Treatment (13 papers) and Nitric Oxide and Endothelin Effects (10 papers). The work is most often cited by research in Oncology (1.6k citations), Immunology (848 citations), Cancer Research (349 citations), Hematology (239 citations) and Molecular Biology (1.5k citations). Wolfram E. Samlowski has collaborated with scholars based in United States, South Korea and United Kingdom. Frequent co-authors include John R. McGregor, John B. Hibbs, Sancy A. Leachman, Raymond A. Daynes, Chang‐Yeol Yim, Steven O’Day, Neil R. Bastian, Evan M. Hersh, Kenneth M. Boucher and Lee D. Cranmer. Their work appears in journals such as Journal of Clinical Oncology, Cancer, Investigational New Drugs, Journal of Immunotherapy and Cellular Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact